CVCA & SLOVCA Awards 2025
MultiplexDX Wins Prestigious Czech-Slovak Impact Award
We are thrilled to announce that MultiplexDX International has been honored with the Impact Deal Award at the 5th annual CVCA & SLOVCA Awards 2025 in the Czech Republic and Slovakia.
Last year, our biotech company achieved an exceptional investment milestone in Slovakia, securing €8.12 million from investors including Crowdberry, Neulogy Ventures, Venture to Future Fund, and Lumus Investment. Additionally, we successfully secured three Recovery Plan grants, totaling €5.6 million. This strong financial support enables us to validate our innovative breast cancer diagnostic test, Multiplex8+, clinically.
This recognition reflects the combination of a substantial investment achievement and meaningful societal impact in healthcare. We are deeply grateful to our investors, scientific,medical, and financial partners, and most importantly, to the oncology patients who have placed their trust in our diagnostic innovation. Thanks to their confidence, many patients were able to find the proper treatment and gain a chance for a longer, healthier life.
Remarkably, initiatives of this global significance are emerging from Slovakia. Even in challenging times, when society faces polarization, misinformation, and a lack of empathy, projects like MultiplexDX demonstrate that Slovakia continues to make a positive mark on the world stage.
About MultiplexDX
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter
